189
Views
142
CrossRef citations to date
0
Altmetric
Review

Recent advances in therapeutic chalcones

, &
Pages 1669-1691 | Published online: 25 Feb 2005

Bibliography

  • SHIMOKORIYAMA M: Ravanones, Chalcones and Aurones. Geissman TA (Ed.) The MacMillan Company, New York, (1962):286–313.
  • SCHRODER J: The chalconeistilbene-synthase type family of condensing enzymes. In: Comprehensive Natural Products Chemistry Sankawa U (Ed.) (1999):749–771
  • BOWN D: Encyclopedia of Herbs and Their Uses. Folkard C (Ed.) Dorling Kindersley Publishing, Inc., New York, (1995):238,289,329,345.
  • AL-NAKIB W, HIGGINS PG, BARROW I: Intranasal chalcone, Ro-09-0410, as prophylaxis against rhinovirus infection in human volunteers. Antimicrob . Chemother. (1988) 20(6):887–892.
  • PHILLPOTTS RJ, HIGGINS PG, WILLMAN JS: Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. Antimicrob. Chemother. (1984) 14(4):403–409.
  • CLUZAN RV, ALLIOT F, GHABBOUN S: Treament of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology (1996) 29(1):29–35.
  • BELTRAMINO R, PENENORY A, BUCETA A: An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic. Angiology (2000) 51(7)535–544.
  • WEINDORF N, SHULTZ -EHRENBURG U: Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatusand trimethylhesperidinchalcone. Z Hautkr (1987) 62(1):28–38.
  • DIMMOCK JR, ELIAS DW, KANDEPU NM: Bioactivities of chalcones. Curr. Med. Chem. (1999) 6(12):1125–1149.
  • OPLETALOVA V, SEDIVY D: Chalcones and their heterocyclic analogues as potential antifungal chemotherapeutics. Ces. Solv. Farm. (1999) 48(6):252–255.
  • OPLETALOVA V, RICICAROVA P, SEDIVY D, MELTROVA D, KRIVAKOVA J: Chalcones and their heterocyclic analogues as potential medicaments. Folia Pharm. Univ. Carol. (2000) 25:21–33.
  • OPLETALOVA V: Chalcones and their heterocyclic analogues as potential therapeutic agents for bacterial diseases. Ces. Solv. Farm. (2000) 49(6):278–284.
  • OPLETALOVA V, JAHODARL JD,24.OPLETAL L: Chalcones (1,3-diarylpropen-1-ones) and their analogues as potential therapeutic agents of diseases of the cardiovascular system. Ces. SoIv. Farm. (2003) 52(1):12–19.
  • HARAGUCHI H, ISHIKAWA H, MIZUTANI K, TAMURA Y, KINOSHITA T: Antioxidative and25.superoxide scavenging activities of retrochalcones in Clycyrrhiza inflata. Bioorg. Med. Chem. (1998) 6(3):339–347.
  • CHENG ZJ, LIN CN, HWANG TL, TENG CM: Broussochalcone A, a potent antioxidant and effective suppressor of26.inducible nitric oxide synthase in lipopolysaccharide-activated macrophages. Biochem. Pharmacol (2001) 16(8):939–946.
  • MIRANDA CL, STEVENS JF, IVANOV V et al: Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and27.flavanones in vitro. J. Agric. Food Chem. (2000) 48(9):3876–3884.
  • LEBEAU J, FURMAN C, BERNIER JL, DURIEZ P TEISSIER E, COTELLE N: Antioxidant properties of di-tert- butylhydroxylated flavonoids. Free Radic Biol.28.Med. (2000) 29(9):900–912.
  • VAYA J, BELINKY PA, AVIRAM M: Antioxidant constituents from licorice roots: isolation, structure elucidation and29.antioxidative capacity toward LDL oxidation. Free Radic Biol. Med. (1997) 23(2):302–313.
  • CIOFFI G, MORALES EL, BRACA A, DE TOMMASI N: Antioxidant chalcone glycosides and flavanones from Madura (Chlorophora) tinctoria. Nat. Prod. (2003)30.66(8):1061–1064.
  • WANG JP, TSAO LT, RAUNG SL, LIN CN: Investigation of the inhibitory effect of broussochalcone A on respiratory burst in neutrophils. Eur. Pharmacol (1997) 320(2–3):201–208.31.
  • HSIEH HK, LEE TH, WANG JP WANG JJ, LIN CN: Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm. Res. (1998) 15(1):39–46.
  • CALLISTE C-A, LE BAIL J-C,32.TROUILLAS P et al.: Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res. (2001) 21:3949–3956.
  • ZHAO F, NOZAWA H, DAIKONNYA A, KONDO K, KITANAKA S: Inhibitors of33.nitric oxide production from hops (Humulus lupulus L.). Biol. Pharm. (2003) 26(1):61–65.
  • ROJAS J, PAYA M, DEVESA I, DOMINGUEZ JN, FERRANDIZ ML: Therapeutic administration of 3,4,5-trimethoxy-4'-fluorochalcone, aselective inhibitor of iNOS expression, attenuates the development of adjuvant-induced arthritis in rats. Naunyn-Schmiedebergs Arch. Pharmacol (2003) 368(3):225–233.
  • CHENG ZJ, LIN CN, HWANG TL, TENG CM: Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipopolysaccharide-activated macrophages. Biochem. Pharmacol (2001) 61(8):939–946.
  • HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 in mouse peritoneal macrophages. FEBS Lett. (1999) 453(1-2):129–134.
  • KO HH, TSAO LT, YU KL, LIU CT, WANG JP, LIN CN: Structure-activity relationship studies on chalcone derivatives. the potent inhibition of chemical mediators release. Bioorg. Med. Chem. (2003) 11(1):105–111.
  • HERENCIA F, LOPEZ-GARCIA MP, UBEDA A: Nitric oxide-scavenging properties of some chalcone derivatives. Nitric Oxide (2002) 6(2):242–246.
  • HERENCIA F, FERRANDIZ ML, UBEDA A et al: 4-Dimethylamino-3',4'-dimethoxychalcone downregulates iNOS expression and exerts anti-inflammatory effects. Free Radic. Biol. Med. (2001) 30(1):43–50.
  • ROJAS J, DOMINGUEZ JN, CHARRIS JE, LOBO GM, PAYA M, FERRANDIZ ML: Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase. Eur. J. Med. Chem. (2002) 37(8):699–705.
  • ROJAS J, PAYA M, DOMINGUEZ JN, LUISA FM: The synthesis and effect of fluorinated chalcone derivatives on nitric oxide production. Bioorg. Med. Chem. Lett. (2002) 12(15):1951–1954.
  • HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 (COX-2) in mouse peritoneal macrophages. FEBS Lett. (1999) 453(1-2):129–134.
  • HERENCIA F, FERRANDIZ ML, UBEDA A et al.: Synthesis and anti-inflammatory activity of chalcone derivatives. Bioorg. Med. Chem. Lett. (1998) 8(10):1169–1174.
  • HSIEH HK, TSAO LT, WANG JP, LIN CN: Synthesis and anti-inflammatory effect of chalcones. Pharm. Pharmacol (2000) 52 (2) :163–171.
  • BARFOD L, KEMP K, HANSEN M, KHARAZMI A: Chalcones from Chinese liquorice inhibit proliferation of T cells and production of cytokines. Int. Immunopharmacol (2002) 2(4):545–555.
  • DE LEON EJ, ALCARAZ MJ, DOMINGUEZ JN, CHARRIS J, TERENCIO MC: A new chloroquinolinyl chalcone derivative as inhibitor of inflammatory and immune response in mice and rats. J. Pharm. Pharmacol (2003) 55(9):1313–1321.
  • DE LEON EJ, ALCARAZ MJ, DOMINGUEZ JN, CHARRIS J, TERENCIO MC: 1- (2,3,4-trimethoxypheny1)-3- (3- (2-chloroquinoliny0)-2-propen-1-one, a chalcone derivative with analgesic, anti-inflammatory and immunomodulatory properties. Infiamm. Res. (2003) 52(6):246–257.
  • BALLESTEROS JF, SANZ MJ, UBEDA A et al.: Synthesis and pharmacological evaluation of 2'-hydroxychalcones and flavones as inhibitors of inflammatory mediators generation. J. Med. Chem. (1995) 38(14):2794–2797.
  • TANAKA S, SAKATA Y, MORIMOTO K et al.: Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules, ICAM-1 and VCAM-1. Planta Med. (2001) 67(2):108–113.
  • MADAN B, BATRA S, GHOSH B: 2'-hydroxychalcone inhibits nuclear factor-KB and blocks tumor necrosis factor-alpha- and lipopolysaccharide-induced adhesion of neutrophils to human umbilical vein endothelial cells. Mol Pharmacol (2000) 58(3):526–341.
  • HOWARD RB, MCDONALD AM, STEFANOPOULOS D et al: The synthetic chalcone AGI-2048 inhibits several indices of diseases in rat adjuvant arthritis. FASEB J. (2003) 17(4):A666.
  • SUNDELL CL, LANDERS UK, QIU FH et al: AGI-2048, a novel synthetic chalcone, inhibits eosinophilia, inflammatory gene expression and airway hyperresponsiveness in a murine asthma medel. Am. J. Respir. Crit. Care Med. (2003) 167:A357.
  • PETTIT GR, SINGH SB, HAMEL E, UN CM, ALBERTS DS, GARCIA-KENDALL D: Isolation and structure of the strong cell growth and tubulin inhibtor combretastatin A-4. Experientia. (1989) 45(2):209–211.
  • LIN CM, SINGH SB, CHU PS et al: Interaction of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol (1988) 34(2):200–208.
  • MOLL UM, PETRENKO 0: The MDM2-p53 interaction. Mol. Cancer Res. (2003) 1(14):1001–1008.
  • O'DWYER PJ, LACRETA F, NASH S et al.: Phase I study of thiotepa in combination with the glutathione trasferase inhibitor ethacrynic acid. Cancer Res. (1991) 51(22):6059–6065.
  • OAKLEY AJ, ROSSJOHN J, BELLO ML, CACCURI AM, FEDRICT G, PARKER MW: The three-dimensional structure of the human Pi class glutathion transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione conjugate. Biochemistry (1996) 36(3):576–585.
  • PLOEMEN JH, BOGAARDS JJ, VELDINK GA, VAN OMMEN B, JANSEN DHM, VAN BLADEREN PJ: Isoenzyme selective irreversible inhibition of rat and human glutathione Stransferases by ethacrynic acid and two brominated derivatives. Biochem. Pharmacol (1993) 45(3):633–639.
  • STOLL R, RENNER C, HANSEN S et al.: Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 40(2):336–344.
  • KUMAR SK, HAGER E, PETTI C, GURULINGAPPA H, DAVIDON NE, KHAN SR: Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. ./. Med. Chem. (2003) 46(14):2813–2815.
  • REED JC: Apoptosis-based therapies. Nat. Rev Drug Dis. (2002) 1:111–121.
  • ZHANG JY: Apoptosis-based anticancer drugs. Nature Rev. Drug Dis. (2002) 1:101–102.
  • RAFI MM, ROSEN RT, VASSIL A et al:Modulation of bc1-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. (2000) 20:2653–2658.
  • Physician's Desk Reference. (1999):3425.
  • KELLOFF GJ, LUBET RA, RL et al.: Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prey (1998) 7(0:65–78.
  • TAMIR S, EIZENBERG M, SOMJEN D, IZRAEL S, VAYA J: Estrogen-like activity of glabrene and other constituents ioslated from licorice root. J. Steroid Biochem. Mol. Biol. (2001) 78:291–298.
  • YAMAZAKI S, MORITA T, ENDO H et al.: Isoligiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett. (2002) 183:23–30.
  • BABA M, ASANO R, TAKAHASHI T et al.: Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol. Pharm. Bull. (2002) 25(2):247–250.
  • BENSON AM, HUNKELER MJ, TALALAY P: Increase of NAD(P)H: quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sri. USA (1980) 77(9):5216–5220.
  • MIRANDA CL, APONSO GL, STEVENS JF, DEINZER ML, BUHLER DR: Prenylated chalcones and flavanones as inducers of quinone reductase in mouse Hepa 1c1c7 cells. Cancer Lett. (2000) 149:21–29.
  • DINKOVA-KOSTOVA AT, MASSIAH MA, BOZAK RE, HICKS RJ, TALALAY P: Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Li. USA (2001) 98(6):3404–3409.
  • HENDERSON MC, MIRANDA CL, STEVENS JF, DEINZER ML, BUHLER DR: LI vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica (2000) 30(3):235–251.
  • BRIDGES AJ: Chemical inhibitors of protein kinases. Chem. Rev (2001) 101(8):2541–2571.
  • YANG EB, GUO YJ, ZHANG K, CHEN YZ, MACK P: Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives. Biochim. Biophys. Acta (2001) 1550:144–152.
  • NAKAMURA C, KAWASAKI N, MIYATAKA H et al.: Synthesis and biological activities of fluorinated chalcone derivatives. Bioorg. Med. Chem. (2002) 10:699–706.
  • SODERSTROM T, WADELIUS M, ANDERSSON SO et al.: 5a-Reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics (2002) 12(4):307–312.
  • STEERS WD: 5a-Reductase activity in theprostate. Urology (2001) 58(6.Supp1.1):17–24.
  • SHIMIZU K, KONDO R, SAKAI K, BUABARN S, DILOKKUNANANT U: A geranylated chalcone with 5a-reductase inhibitory properties from Artocarpus incisus. Phytochemistry (2000) 54:737–739.
  • DUCKI S, FORREST R, HADFIELD J et al.: Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. (1998) 8:1051–1056.
  • ROSS SA, ZAGLOUL A, NIMOF A, MEHMEDIC Z, SOHLY EN: A cytotoxic chalcone from Faramea salicifolia. Planta Med. (1999) 65(2):194.
  • DIMMOCK JR, JHA A, ZELLO GA et al.: Cytotoxic 4'-aminochalcones and related compounds. Pharmazie (2003) 58(4):227–232.
  • DIMMOCK JR, PERJESI P: Synthesis and antitumor activities of some cyclic chalcones. Cyogyszereszet (2001) 45(4):210–215.
  • HARAGUCHI H, TANIMOTO K, TAMURA Y, MIZUTAN K, KINOSHITA T: Mode of antibacterial action of retrochalcones from Cbxyrrhiza inflate. Phytochernistry(1998) 48(1):125–129.
  • KABIR AM, SHIMIZU K, AIBA Y, IGARASHI M, TAKAGI A, KOGA Y: The effect of sofalcone on indomethacin-induced gastric ulcers in a Helicobacter pylori-infected gnotobiotic murine model. Aliment Pharmacol Ther. (2000) (Suppl. 0:223–229.
  • FRITS-MOLLER A, CHEN M, FUURSTED K, CHRISTENSEN SB, KHARAZMI A: In vitro antimycobacterial and antilegionella activity of licochalcone A from Chinese licorice roots. Planta Med. (2002) 68(5):416–419.
  • ZHAI L, CHEN M, BLOM J, THEANDER TG, CHRISTENSEN SB, KHARAZMI A: The anitleishmanial activity of novel oxygenated chalcones and their mechanism of action. J. Antimicro. Chemother. (1999) 43:793–803.
  • KAYSER 0, KIDERLEN AF: In vitro Leishmanicidal activity of naturally occurring chalcones. Phytother: Re.s (2001) 15:148–152.
  • NIELSEN SF, CHRISTENSEN SB, CRUCIANI G, KHARAZMI A, LILJEFORS T: Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. (1998) 41(204819–4832.
  • LIU M, WILAIRAT P, GO M-L: Antimalarial alkoxylated and hydroxylated chalcones: structural-activity relationship analysis. J. Med. Chem. (2001) 44(25):4443–4452.
  • LIN Y-M, ZHOU Y, FLAVIN MT, ZHOU L-M, NIE W, CHEN F-C: Chalcones and flavonoids as anti-tuberculosis agents. Bioorg. Med. Chem. (2002) 10:2795–2802.
  • ELSOHLY HN, JOSHI AS, NIMROD AC, WALKER LA, CLARK AM: Antifungal chalcones from Madura tinctoria. Planta Med. (2001) 67:87–89.
  • CHEN M, ZHAI L, CHRISTENSEN SB, THEANDER TG, KHARAZMI A: Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob. Agents Chemother. (2001) 45(7):2023–2029.
  • VIANA GS, BANDEIRA MA, MATOS FJ: Analgesic and anti-inflammatory effects of chalcones isolated from Myracrodruon urundeuva allemao. Phytomedicine (2003) 10(2-3):189–195.
  • LIN CN, LEE TH, HSU ME WANG JP, KO FN, TENG CM: 2',5'-Dihydroxychalcone as a potent chemical mediator and cyclooxygenase inhibitor. J. Pharm. Pharmacol (1997) 49(5):530–536.
  • LIN CN, LU CM, LIN HC etal.: Novel antiplatelet constituents from formosan moraceous plants. J. Nat. Prod. (1996) 59(9):834–838.
  • ZWAAGSTRA ME, TIMMERMAN H, TAMURA M et al.: Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists. Med . Chem. (1997) 40(7):1075–1089.
  • KIM YP, BAN HS, LIM SS et al: Inhibition of prostalglandin E2 production by 2'-hydoxychalcone derivatives and the mechanism of action. ./. Pharm. Pharmacol (2001) 53(9):1295–1302.
  • LEE YN, YEH HI, TIAN TY, LU WW, KO YS, TSAI CH: 2',5'-Dihydroxychalcone down-regulates endothelial connexin 43 gap junctions and affects MAP kinase activation. Toxicology (2002) 179(1-2):51–60.
  • MATSUURA M, KIMURA Y, NAKATA K, BABA K, OKUDA H: Artery relaxation by chalcones isolated from the roots of Angelica keiskei. Planta Med. (2001) 76(3):230–235.
  • AIDA K, TAWATA M, SHINDO H et al: Isoliquiritigenin: a new aldose reductase inhibitor from Clycyrrhizae radix Planta Med. (1990) 56(3):254–258.
  • LIM SS, JUNG SH, JI J, SHIN KH, KEUM SR: Inhibitory effects of 2'-hydroxychalcones on rat lens aldose reductase and rat platelet aggregation. Chem. Pharm. Bull. (2000) 48(10:1786–1789.
  • TAWATA M, AIDA K, NOGUCHI T eta/.: Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. Eur. Pharmacol (1992) 212(1):87–92.
  • MENG CQ, ZHENG XS, NI L etal.: Discovery of novel heteroaryl-substituted chalcones as inhibitors of TNF-a-induced VCAM-1 expression. Bioorg. Med. Chem. Lett. (2004) 14:1513–1517.
  • MIDDLETON E, KANDASWAMI C, THEOHARIDES TC: The effects of plant flavonoids on mammalian cells: implication for inflammation, heart desease, and cancer. Pharmacol Rev. (2000) 52 (4) :673–751.
  • O'NEILL PM, POSNER GH: A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. (2004) 47(12):2945–2964.

Websites

  • http://www.herbmed.org/herbs/herb101.htm HerbMed® — Glycyrrhiza glabra (Licorice).
  • •This website provides lists of research literatures of various medical herbs.
  • http://www.herbmed.org/herbs/herb24.htm HerbMed® — Angelica sp. (Angelica).
  • •This website provides lists of research literatures of various medical herbs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.